Transcenta cleared to advance gremlin-1-targeting antibody TST-003 into clinic for solid tumors
Sep. 14, 2022
Transcenta Holding Ltd. has received IND clearance from the FDA for TST-003, its first-in-class, high-affinity, humanized monoclonal antibody targeting gremlin-1.